Provided by Tiger Trade Technology Pte. Ltd.

Crescent Biopharma Inc

11.47
-0.1800-1.55%
Pre-market: 11.24-0.2300-2.01%08:00 EST
Volume:88.65K
Turnover:1.02M
Market Cap:316.08M
PE:-0.52
High:11.80
Open:11.40
Low:11.04
Close:11.65
52wk High:29.23
52wk Low:8.72
Shares:27.56M
Float Shares:10.87M
Volume Ratio:0.36
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.9706
EPS(LYR):-3.3635
ROE:-182.66%
ROA:-73.99%
PB:4.36
PE(LYR):-3.41

Loading ...

Company Profile

Company Name:
Crescent Biopharma Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
6
Office Location:
300 Fifth Avenue,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Directors

Name
Position
Joshua Brumm
Chief Executive Officer and Director
Alexandra Balcom
Independent Director
David Lubner
Independent Director
Peter Harwin
Chair and Independent Director
Susan Moran
Independent Director
Jonathan Violin
Director

Shareholders

Name
Position
Joshua Brumm
Chief Executive Officer and Director
Jonathan McNeill
Chief Operating Officer and President
Richard Scalzo
Chief Financial Officer
Ryan Lynch
Chief Accounting Officer and Senior Vice President of Finance and Treasurer
Barbara Bispham
Corporate Secretary and General Counsel
Christopher Doughty
Chief Business Officer
Ellie Im
Chief Medical Officer
Jan Pinkas
Chief Scientific Officer